Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07144280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07144280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
September 29, 2025
Completion date
March 10, 2032
Enrollment
680 (estimated)
Sites
447

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell carcinoma, non-small cell lung cancer metastatic, non-small cell lung carcinoma